Nektar Therapeutics

NASDAQ: NKTR
$23.36
-$0.67 (-2.8%)
Closing price July 13, 2020
Nektar Therapeutics (NASDAQ: NKTR) saw its shares get nearly halved in Monday’s session after the company released preliminary data from its early stage cancer study. The preliminary results...
Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates.
These four red-hot Jefferies growth stock picks could have substantial upside, especially if the market simmers down some.
With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017.
The top analyst upgrades, downgrades and other research calls from Thursday include Biogen, Cabot Oil & Gas, CenturyLink, NetApp, Square, T-Mobile and Wix.com.
The top analyst upgrades, downgrades and other research calls from Tuesday include Altice USA, CVS Health, Exxon, Lowe's, T-Mobile, Sprint and Under Armour.
The top analyst upgrades, downgrades and other research calls from Monday include BlackBerry, BP, Camping World, Deere, GrubHub, KLA-Tencor, Teva Pharmaceutical and Zions Bancorp.
The top analyst upgrades, downgrades and initiations seen on Monday include AK Steel, Amazon.com, AngloGold Ashanti, Bank of America, General Electric, Walt Disney and Xilinx.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Carnival, Facebook, Freeport-McMoRan, Motorola Solutions and Procter & Gamble.
Esperion Therapeutics and a few other biopharma stocks made massive runs on Monday morning.
The top analyst upgrades, downgrades and initiations seen on Friday, January 6, include Cognizant Technology Solutions, Etsy, GoPro, Illumina, Shake Shack and Travelers Companies.
With the busiest earnings week behind us, it appears some of the restriction windows at major U.S. corporations are starting to open up a little.
Nektar Therapeutics plans to price 13 million shares at $13.50 for a secondary offering valued up to almost $202 million.
The top analyst upgrades, downgrades and initiations seen on Monday, February 8 include Athenahealth, Baker Hughes, Cisco, LinkedIn, Orbital-ATK and Tableau Software.
The analysts at Cowen have calculated the buys and sells in the NYSE Arca Biotechnology Index based on the holdings in the First Trust Biotechnology ETF.